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An important but little examined aspect of radiation dosimetry studies involving organs outside
the treatment field is how to assess dose to organs that are partially within a treatment field; this
question is particularly important for studies intended to measure total absorbed dose in order to
predict the risk of radiogenic late effects, such as second cancers. The purpose of this investigation
was therefore to establish a method to categorize organs as in-field, out-of-field or partially infield that would be applicable to both conventional and modern radiotherapy techniques. In this
study, we defined guidelines to categorize the organs based on isodose inclusion criteria,
developed methods to assess doses to partially in-field organs, and then tested the methods by
applying them to a case of intensity-modulated radiotherapy for hepatocellular carcinoma based on
actual patient data. For partially in-field organs, we recommend performing a sensitivity test to
determine whether potential inaccuracies in low-dose regions of the DVH (from the treatment
planning system) have a substantial effect on the mean organ dose, i.e. >5%. In such cases, we
suggest supplementing calculated DVH data with measured dosimetric data using a volumeweighting technique to determine the mean dose.

1. Introduction
Studies evaluating late effects, such as second cancer risk, require accurate knowledge of
both primary and stray radiation in order to accurately estimate the risk to organs throughout
the body (Boice et al 1985, Stovall et al 1989, 2006, Bhatia et al 2003, Ron 2003, Rubino et
al 2003a, 2003b, Lin and Teitell 2005, Newhauser et al 2009). For organs within a treatment
field, radiation doses are relatively high and attributed mainly to primary radiation. As the
distance from the treatment field increases and the organs become peripheral to the
treatment field, the doses become progressively lower and are attributed mainly to stray
radiation (Stovall et al 1995).
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In-field radiation doses can be accurately and rapidly calculated using commercially
available treatment planning systems (TPSs) (Aspradakis et al 2003, Van Esch et al 2006).
These TPSs do not, however, accurately model doses outside the treatment field, nor are
they commissioned for such calculations (Das et al 2008). A recent study evaluated the
accuracy with which a commercial TPS calculated absorbed dose in regions where the
isodose lines reported by the TPS were less than 5% of the prescribed dose (Howell et al
2010). That study demonstrated that in this very low stray dose region, the predicted doses
were at worst 60% lower than corresponding measured data and that the accuracy of the TPS
calculated doses decreased with increasing distance from the treatment field. An important
consideration in determining peripheral organ doses from stray radiation is the definition of
the field border. In conventional photon radiation therapy, out-of-field organs are easily
defined by their proximity to the field border which is defined by the collimating jaws.
However, for modern photon radiation therapy where fields are defined by modulated beam
intensities it is difficult to definitively define a field border. Dose calculations by a TPS may
also be precluded by a lack of imaging information related to the organs in question:
patients' computed tomography (CT) scans typically include only the anatomy required for
treatment planning and nearby organs or structures at risk, in keeping with the best practices
of avoiding unnecessary exposure (Goske et al 2009). These datasets typically extend only a
few centimeters above and below the target volume. Most treatment planning CT scans
therefore contain incomplete information on peripheral organs that nevertheless receive lowdose stray radiation during treatment.
Measurements obtained using thermoluminescent dosimeters (TLDs) in an anthropomorphic
phantom are widely used for determining peripheral organ doses from photon radiation
therapy. Measurements in phantom are accurate over a broad range of doses and closely
reproduce the irradiation of a patient. In addition, measurement techniques are not limited by
the extent of CT datasets. Radiation dose measurements in anthropomorphic phantoms are
considered the gold standard in peripheral dose assessment and have frequently been used to
determine peripheral organ doses in studies of radiation-induced late effects from photon
radiotherapy (Stovall et al 1989, 2006, Carr et al 2002, Meeks et al 2002, Sigurdson et al
2005, Klein et al 2006, Reft et al 2006, Xu et al 2008). However, measurements in phantom
are very time consuming and require special measurement equipment. Computational
techniques such as Monte Carlo modeling are an alternative approach to measurements for
determining peripheral organ doses. Such simulations can accurately calculate peripheral
organ dose, provided the model is benchmarked for out-of-field doses (Kry et al 2006,
Bednarz and Xu 2009). However, this approach requires computing resources and the CT
datasets should include the patient's complete anatomy or replace missing anatomy with
phantom substitutes.
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Although it is well understood how to calculate dose to organs inside the treatment field and
how to measure or calculate dose to organs outside the treatment field, relatively little
attention has been paid in the literature to dosimetry for organs that are partially within the
treatment field. In particular, the accuracy of the TPS calculations for such organs,
especially when reported in terms of mean organ dose, has not been described. Commercial
TPSs may be inadequate for this task due to inaccuracies in the out-of-field component of
the organ dose, but simulations and phantom studies are prohibitively time consuming and
costly for routine use. Thus, there is a need for a method to determine when the TPSpredicted dose is adequate and when it is not. Such a method should be generally applicable
to either conventional radiation therapy or modern radiation therapy with modulated beam
intensities. This methodology will be particularly helpful when analyzing risk for second
cancers and other late effects, where the total dose from both high-dose primary radiation
and low-dose stray radiation must be known. Thus, the objectives of this investigation
therefore were to establish a method to categorize organs as in-field, out-of-field or partially
Phys Med Biol. Author manuscript; available in PMC 2010 December 13.
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in-field that is applicable to both conventional and contemporary radiotherapy techniques; to
evaluate the accuracy of the mean organ dose reported by a widely used TPS for organs
partially within the treatment field; and to use this evaluation to establish a consistent
methodology for determining doses to such organs in radiotherapy. The categorization of
organs as in-field, out-of-field or partially in-field was based on isodose inclusion criteria
rather than on proximity to the field border. We used dose volume histograms (DVHs) from
the TPS to quantify mean organ doses for in-field organs and measurements in an
anthropomorphic phantom to estimate mean doses for out-of-field organs. We then defined
guidelines to evaluate the potential effect of inaccuracies in the low-dose components of
DVHs for partially in-field organs to determine the effect on the mean organ doses reported
by the TPS. This new methodology was tested on an example case for a patient receiving
intensity-modulated radiotherapy (IMRT) for liver cancer. We chose this one case because
IMRT is a complex photon therapy delivery technique and would allow us to rigorously test
the methodology described in this study. We chose to focus this study on 6 MV because it is
the most commonly used beam energy for IMRT. We choose this particular case because we
had a full body CT scan allowing us to examine all three categories of organs including in
field, out-of-field and partially in-field. Additionally, the treatment plan for this case
included a wide range of doses including low doses. These low doses are of particular
interest for late effects studies.
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2. Materials and methods
2.1. Treatment planning
This study was carried out under an institutional review board-approved protocol for
retrospective treatment planning studies. Dosimetric assessments and evaluations were
based on a case of liver cancer treated at our institution. We selected this site because of our
interest in comparing the risk of secondary malignant neoplasms from different treatment
techniques for liver cancer (Taddei et al 2010). The planning CT scan was acquired using a
2.5 mm slice thickness and included anatomy from the head to mid-thigh for a man (age 59,
height 174 cm and weight 93.9 kg) who had been diagnosed with primary hepatocellular
carcinoma.
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Using a commercial TPS (Eclipse version 8.6, Varian Medical Systems, Palo Alto, CA), we
developed an IMRT plan for this patient with 6 MV photons. The anisotropic analytical
algorithm with tissue heterogeneity corrections and a 2.5 mm calculation grid was used for
dose calculations. The prescribed dose was 60 Gy in 30 fractions (2 Gy/fraction) with the
criterion that 95% of the planning target volume was to receive 100% of the prescribed dose
(D95 = 60 Gy). The treatment plan had nine dynamic multileaf collimator-shaped IMRT
beams. The following structures were contoured for treatment planning: clinical target
volume (CTV), liver, healthy liver (liver minus CTV), right (ipsilateral) kidney, left
(contralateral) kidney, spinal cord, esophagus, lungs and stomach plus duodenum. Table 1
details the planning constraints and the final dosimetric treatment plan values. The final
treatment plan was reviewed and approved by a board-certified radiation oncologist. In
addition to the organs defined for treatment planning, other organs and tissues that are
sensitive to radiogenic late effects were contoured, namely the bone marrow, bone surface,
brain, eyes, thyroid, heart, breast, colon, bladder, rectum, prostate and testicles.
The treatment planning system (and the AAA dose calculation algorithm) used in this study
was fully commissioned and validated for use in our clinic by American Board of Radiology
certified medical physicists using the methodology described by Das et al (2008). The
validation included comparisons of measured and calculated doses for both conventional and
IMRT treatment plans within the treatment fields and penumbra (penumbra defined as the
distance between the 90% and 10% isodoses). Additionally, the treatment planning system
Phys Med Biol. Author manuscript; available in PMC 2010 December 13.
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was credentialed by the Radiological Physics Center (RPC, Houston, TX) for the use of
IMRT in clinical trials following RPC credentialing protocols (Ibbott et al 2006, Followill et
al 2007). Out-of field dose assessment is typically not part of TPS commissioning and was
not considered during the commissioning of the TPS used in this study. The Eclipse AAA
models stray radiation using a finite-size virtual source with a Gaussian intensity distribution
(Sievinen et al 2005).
2.2. Measurement locations in the phantom
In this study, we used a commercial male dosimetry phantom (ATOM, CIRS, Inc., Norfolk,
VA) for dose measurements, figure 1. The phantom is transected horizontally in 2.5 cm
slices and was custom fabricated to include a 1.5 cm2 grid of holes to hold TLD capsules as
well as additional optimized TLD capsule locations for precise dosimetry in 20 internal
organs. A CT scan of the phantom was acquired using a 2.5 mm slice thickness, which was
then imported into the TPS. The phantom's organs were contoured using the image
segmentation tools in the TPS and an organ map provided by the phantom manufacturer.
The patient and phantom CT datasets were registered by manual vertebral body matching
using registration tools within the TPS. After the CT datasets were registered, the patient's
treatment plan was superimposed on the phantom CT dataset. The plan isocenter in the
phantom was defined using the anterior and right lateral set-up fields from the patient's
treatment plan.
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The out-of-field measurement locations within the phantom were determined by selecting
TLD locations that were within the organ map but outside the 5% isodose line. The heart
was also an out-of-field organ, but because the organ map does not include locations for the
heart, TLD positions for this organ were defined independently by manual selection of
locations within the 1.5 cm2 grid that correlated with structures in the heart based on visual
inspection of the CT dataset.
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The distance between the centroid of each out-of-field organ and the nearest 5% isodose line
was determined to evaluate the relationship between mean organ dose and distance from the
treatment field edge. We used distance from the 5% isodose line as a surrogate for distance
from any particular field border because the treatment plan in this study included both
obliquely incident and non-coplaner beams and thus it was difficult to define a single field
edge. The coordinates of the center of each organ were determined using measurement tools
in the TPS. Then we calculated the difference between the z-coordinate of the organ centroid
and the z-coordinate of either the superior or inferior 5% isodose line, as appropriate. This
process is illustrated in figure 2, which shows the superior and inferior 5% isodose lines and
the distances from them for an organ superior to the target volume (brain) and an organ
below it (bladder). Similar measurements were made for each out-of-field organ.
2.3. Measurements in the phantom
Lithium fluoride TLD-100 powder capsules (Quantaflux Radiological Services, San Jose,
CA) were selected for the in-phantom measurements. All TLD capsules were from the same
batch to avoid batch-to-batch variations in sensitivity. The TLD capsules were loaded into
the phantom at the positions specified above. The phantom was set up on a commercial
medical linear accelerator (Varian Clinac 2100, Varian Medical Systems, Palo Alto, CA)
treatment couch to the isocenter. The planned treatment fields were then delivered to the
phantom as specified in the treatment plan. The linac used in this study is calibrated monthly
for in-field dose using the American Association of Physicists in Medicine Task Group 51
protocol (Almond et al 1999). Additionally, for this study, the output was verified on the
day of experimental measurements.
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Following irradiation, the TLDs were individually read using an established laboratory
protocol consistent with Accredited Dosimetry Calibration Laboratory procedures, which
accounts for energy response, linearity and dosimeter fading and has an uncertainty of
<3.0% (Kirby et al 1986, 1992). The TLD readings were converted to absorbed dose in
tissue using a calibration coefficient from a set of reference TLDs (from the same batch)
irradiated with Co-60. The Co-60 unit that was used to irradiate the TLD standards was
certified and maintained by an Accredited Dosimetry Calibration Laboratory and was
calibrated traceable to standards of the National Institute of Standards and Technology. The
mean organ dose (and standard deviation) was calculated from all TLDs within each organ.
All measured doses were normalized per absorbed dose delivered to the isocenter and are
reported in Gray per prescribed Gray (Gy/GyRx).
2.4. Organ classification and methods for dose assessment for each organ category
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The definition of in-field organs is not as straightforward for advanced radiotherapies as it is
for conventional techniques. In conventional radiotherapy, in-field organs are those that lie
wholly within the regions defined by the collimating devices. For IMRT, conversely, the
treatment fields are defined by modulated beam intensities rather than by static collimation.
Consequently, we sought to define organs as in-field, out-of-field or partially in-field based
on criteria other than distance from the field edge but that are generally applicable to both
conventional radiotherapy and IMRT. Aspradakis et al (2003) found that doses reported by
several modern TPSs are accurate within the treatment field and up to approximately 3 cm
beyond the field edge. Additionally, in a recent study (Howell et al 2010) we found that the
TPS used in this study underreported dose at distances greater than 3.5 cm beyond the field
edge, corresponding to regions where the isodose lines were less than 5% of the prescribed
dose. Based in part on the evidence from the above studies, we proposed to categorize
organs as in-field, out-of-field or partially in-field using an isodose inclusion criterion,
namely the 5% isodose level, as a conservative and generally applicable defining metric. We
defined organs as being out-of-field if no part of the organ received more than 5% of the
prescribed dose. We defined organs as in-field if the entire organ (100% of the volume)
received more than 5% of the prescribed dose. We defined partially in-field organs as those
that did not meet the in-field criterion but could not be classified as out-of-field. An example
of two partially in-field organs, the lungs and left kidney, are shown in figure 3. This figure
is the frontal view of the patient CT dataset at the isocenter plane with the dose displayed as
a color wash from the maximum dose of 112.9% to 0.1% of the prescribed dose. The 5%
isodose line is outlined using a green contour and the out-of-field and in-field portions of the
lungs and left kidney are shown in orange and white contours, respectively.
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The mean doses for in-field organs were calculated using DVH data from the TPS, as is a
standard practice in radiation treatment planning. The mean doses for out-of-field organs
were determined using measured TLD measurements (described above in section 2.3). The
mean doses to partially in-field organs were first calculated using DVH data from the TPS
and then examined in terms of the sensitivity of the mean dose to inaccuracies in the lowdose component of the TPS data and adjusted accordingly (described below in section 2.5).
2.5. Partially in-field organs: sensitivity analysis and volume-weighting technique
Inaccuracy in low-dose regions may affect the low-dose component of DVH data for
partially in-field organs. This inaccuracy may in turn affect the mean organ dose reported by
the TPS, providing the rationale for investigating the potential effect of the low-dose
component of the DVH data on the mean organ doses. Our previous finding of maximum
difference of 60% (Howell et al 2010) between doses reported by the TPS (used in this
study) and measured doses in regions outside the 5% isodose line prompted us to conduct a
sensitivity analysis of how inaccuracy in the low-dose region of the DVH may affect the

Phys Med Biol. Author manuscript; available in PMC 2010 December 13.
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mean organ doses. Thus, we performed a sensitivity test to assess how much over- or
underestimation of dose in the out-of-field region affects the reported mean dose of a
partially in-field organ. Specifically, we calculated the mean organ doses after adjusting the
absorbed dose by +60% and −60% for portions of the DVH with dose less than 5% of the
prescribed dose. We selected 60% deviation to add a degree of conservatism to the
sensitivity analysis. This method is illustrated in figure 4 for the two partially in-field organs
shown in figure 3.
The adjusted mean doses were then compared to the mean doses reported by the TPS. If the
adjusted means were within ±5% of those reported by the TPS, then TPS data alone were
used to determine the mean organ dose, otherwise we used a volume-weighting technique to
calculate the mean organ dose described below. The 5% criterion was chosen based on
evidence that accuracy to within approximately ±5% in dose delivery (95–105% of the
prescribed dose) is necessary for effective radiotherapy (ICRU 1987).
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Volume-weighted mean organ doses were determined by taking a volume-weighted average
of the in-field and out-of field components of dose. Each partially in-field organ was divided
into two components: (1) in-field component (i.e. the portion of the organ within the 5%
isodose surface) and (2) out-of-field component (i.e. the portion of the organ outside the 5%
isodose surface). These sub-volumes were created using the Boolean operation tools in the
TPS. The volume of each organ component was determined using a volume measurement
tool in the TPS. The in-field component was taken as the volume-weighted mean dose of the
in-field portion of the organ calculated by the TPS, and the out-of-field component was
determined using a volume-weighted mean dose from TLD measurements. As previously
stated, these calculations were only performed for partially in-field organs where sensitivity
analysis revealed that inaccuracies in low-dose regions of the DVH had a substantial effect
on the accuracy of the mean organ dose.
Less than one-quarter of the colon, bone marrow and bone surface volumes (21%, 10% and
11%, respectively) were within the 5% isodose line. Additionally, significant fractions of
these organs were entirely outside of the maximum achievable calculation region of the TPS
(i.e. reported as zero dose). Thus, we used the volume-weighted technique to calculate mean
doses for the colon, bone marrow and bone surface but did not perform sensitivity analysis
because they were obviously partially in-field.

3. Results
3.1. Organ classifications
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For the case described here, in-field organs included the right kidney, liver and stomach.
Out-of-field organs included the brain, eyes, thyroid, heart, breasts, bladder, rectum, prostate
and testicles. Partially in-field organs included the left kidney, lungs, spinal cord, esophagus,
colon, bone marrow and bone surface.
3.2. In-field and out-of-field organ doses
Mean doses for the in-field and out-of-field organs are listed in table 2. Figure 5 shows the
TLD-measured doses to the out-of-field organs as a function of the distance from the 5%
isodose line to the center of each organ. The error bars on each data point in figure 5
represent the standard deviation in the measured dose among all TLDs within the organ.
Data in figure 5 show that standard deviation depends on the dose gradients, i.e. there is
lower deviation in dose for organs that are farther from the treatment field.

Phys Med Biol. Author manuscript; available in PMC 2010 December 13.
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Table 3 lists the mean doses to the left kidney, lungs, spinal cord and esophagus calculated
using the DVH data from the TPS. In addition, table 3 lists the adjusted mean doses for
those organs calculated assuming dosimetric errors of +60% and −60% for all portions of
the DVH with dose less than 5% of the prescribed dose. Examples of the sensitivity analysis
on the accuracy of the low-dose component of the TPS data for partially in-field organs are
presented for the lungs and left kidney in figure 4, which shows the original DVH and the
DVHs with the low-dose component adjusted assuming dosimetric errors of +60% and
−60%. Similar analyses were performed for the spinal cord and esophagus (data not shown).
In these figures, there is a discontinuity in the modified DVHs. This exists because we
applied the single adjustment of 60% to all dose values below 5% of the prescription dose
rather than a scaling function which would have resulted in physically valid curves. This
single factor was applied to provide the most conservative metric for the sensitivity analysis.
These discontinuous DVHs would not be usable for dose assessment, but only to determine
whether out-of-field dose measurements are warranted.
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For the lungs, spinal cord and esophagus, the adjusted mean doses were within ±5% of the
mean doses reported by the TPS. Therefore, we used DVH data from the TPS alone to
assess the mean organ doses to these partially in-field organs. For the left kidney, however,
the adjusted mean dose was substantially greater than 5% of the mean dose reported by the
TPS. Therefore, we used the volume-weighted technique to assess the mean dose for the left
kidney. The mean TPS-calculated left kidney dose, 51.8 mGy/GyRx (see table 3), was
approximately 13% lower than the volume-weighted dose, 59.7 mGy/GyRx (see table 4),
calculated from both DVH and measured data. Table 4 also lists the volume-weighted mean
doses for the colon, bone marrow and bone surface.

4. Discussion
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In this study, we established a method to categorize organs as in-field, out-of-field or
partially in-field based on isodose inclusion criteria. We used DVHs from the TPS to
quantify mean organ doses for in-field organs and measurements in an anthropomorphic
phantom to estimate mean doses for out-of-field organs. The study met its objective to
evaluate TPS calculations for organs partially within the treatment field and used this
evaluation to establish a consistent methodology for determining doses to such organs. We
recommend that if inaccuracies in low-dose regions of the DVH will have little effect on the
mean organ dose (<±5%), TPS data alone may be used to estimate the mean organ dose. But
if inaccuracies in low-dose regions of the DVH have a more substantial effect on the mean
organ dose (>5%), we suggest using the volume-weighting technique described here to
determine the mean dose.
In conventional photon therapy, the out-of-field dose decreases rapidly as the distance from
the field edge increases (Stovall et al 1995). For IMRT cases, as in the example presented
here, the field edge cannot always be clearly defined. However, the data follow the same
trend when the distance from the field edge is replaced by the distance from the 5% isodose
line in analyses. Our data showed that among out-of-field organs those closest to a 5%
isodose line received the highest doses with the greatest variability in dose within the organ.
We attribute this pattern to the stray radiation inherent in the treatments. As the distance
from the field edge (in conventional therapy) or from the 5% isodose line (in IMRT)
increases, stray radiation contributions change from being composed of both scatter and
leakage radiation to leakage radiation only (Fraass and van de Geijn 1983, Stovall et al
1995, Chofor et al 2010). This change is important when designing phantom measurements
because there is minimal intra-organ deviation in dose far outside the field (>20 cm) so
fewer TLDs would be required to determine mean organ doses.
Phys Med Biol. Author manuscript; available in PMC 2010 December 13.
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A limitation of the present study was that the criterion for the sensitivity analysis was based
on an assumption of a 60% error in the dose reported by the treatment planning system for
doses less than 5% of the prescription dose. This value was based on data from a previous
study for a particular treatment plan calculated using the Eclipse TPS version 8.6 and Varian
2100 Clinac. The exact under- or over-estimation in the out-of-field dose reported for
different treatment plans, calculated using different TPSs and linac combinations, is
dependent on the particular algorithm used, the commissioning data and the manufacturer.
Nonetheless, the 60% assumption used in this study is a conservative estimate because this
represents the maximum deviation that was observed in our previous study. At present there
are limited data in the literature regarding out-of-field dose, especially for modern radiation
therapy. Recently Xu et al (2008) surveyed the literature for dosimetry studies on external
beam radiation treatment and reported 23 studies that considered out-of-field dose from
IMRT. The majority of those studies involved measurements and the remainder used Monte
Carlo methods. None compared the out-of-field doses to those reported by the treatment
planning systems. However, as such data become available, the methodology described in
this study can be easily customized with different criterion for the sensitivity analysis for
different treatment plan types, planning systems, linacs and commissioning parameters.
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This study demonstrated that for some partially in-field organs, the DVH as determined by
the TPS underestimated the mean dose by approximately 15%. The focus of this work is on
low doses, which may not affect patient care decisions. However, accurate assessment of
out-of-field dose is very important in evaluating late effects such as second cancers and for
developing dose response models for these low dose effects. For such studies, if part of an
organ receives a very large dose and only a small fraction of the volume receives a low dose
(such as the lungs in this study), TPS DVHs can be used. However, in scenarios where a
majority of the organ volume receives less than 5% of the prescribed dose and little or none
of the volume is in a high-dose gradient (such as the left kidney in this study), it would be
prudent to perform a sensitivity analysis, as described here. Results of the sensitivity
analysis may then be used to determine whether supplementing TPS calculations with
measured data is warranted.

5. Conclusion
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The method for assessing organ doses throughout the body from photon radiotherapy
described here can be used in studies that require accurate knowledge of a wide range of
doses from both primary and stray radiation. Such broad information will be of particular
use in studies of radiation-induced late effects, which require accurate knowledge of doses
to in-field, outof-field and partially in-field organs to predict the risk to organs throughout
the body. For example, the methodology established in this study for categorizing organs
and determining doses to partially in-field organs may be applied in comparative
effectiveness research studies that evaluate both acute and late effects from different
radiotherapy treatment techniques.
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Figure 1.

Photograph of ATOM male dosimetry phantom (CIRS, Inc., Norfolk, VA) used in this
study.
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Figure 2.

Illustration of how the distance between the center of each out-of-field organ and the border
of the nearest 5% isodose line was determined, showing the superior and inferior 5% isodose
lines (green) and the distances from these lines for organs above (brain, pink line) and below
(bladder, yellow line) the lines.
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Figure 3.

Frontal view of the patient CT dataset at the isocenter plane with the dose displayed as a
color wash from the maximum dose of 112.9% to 0.1% of the prescribed dose and showing
two partially in-filed organs, the lungs and the left kidney. The 5% isodose line is outlined
using a green contour and out-of-filed and in-field portions of the lungs and left kidney
shown in orange and white contours, respectively.
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Figure 4.

TPS data for the left kidney (a) lungs (b) and esophagus (c) showing the original DVH
calculated by the TPS and the adjusted DVHs for regions receiving less than 5% of the
prescribed dose (i.e. low-dose regions) adjusted assuming dosimetric errors of +60% and
−60%.
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TLD-measured mean organ dose for the out-of-field organs (primary y-axis) and the
relationship between the mean dose of the distance from the center of each organ to the
nearest 5% isodose line (secondary y-axis). The error bars on each mean dose data point
represent standard deviations in measured doses among all TLDs within the organs.
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Normal-tissue objectives used for treatment planning and corresponding values from the final actual treatment
plan. Vx represents the percentage of volume receiving x Gy of dose, and D95 represents the dose received by
95% of the volume.
Structure

Dosimetric parameter

Prescribed

Actual

Planning target volume

D 95

60 Gy

60.0 Gy

Liver-clinical target volume

V 30

<40%

21.2%

Right (ipsilateral) kidney

V 20

<50%

50.9%

Left (contralateral) kidney

V 20

<30%

0.0%
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Mean organ absorbed dose values and standard deviations (variation about the mean) for out-of-field organs
from TLD measurements and for in-field organs from TPS calculations.
Organ

Mean dose (Gy/GyRx)

Standard deviation

Out-of-field
Brain

2.5 × 10−3

0.9 × 10−3

Eyes

2.5 ×

10−3

0.2 × 10−3

Thyroid

7.6 × 10−3

1.8 × 10−3

22.1 × 10−3

9.0 × 10−3

10−3

3.9 × 10−3

Bladder

5.3 × 10−3

4.2 × 10−3

Rectum

2.8 × 10−3

1.1 × 10−3

Prostate

2.1 × 10−3

0.7 × 10−3

10−3

0.2 × 10−3

Heart
Breast

Testicles

23.7 ×

1.2 ×

In-field
4.54 × 10−1

3.73 × 10−1

Spinal cord

2.35 ×

10−1

1.93 × 10−1

Esophagus

1.87 × 10−1

2.62 × 10−1

Liver-CTV

3.38 × 10−1

2.91 × 10−1

Stomach

1.75 × 10−1

0.90 × 10−1

Right kidney
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Mean doses for partially in-field organs from DVHs calculated by the TPS and the retrospectively adjusted
mean doses computed assuming dosimetric errors of+60% and −60% for all portions of the DVH with dose
less than 5% of the prescribed dose.
Organ: calculation method

Mean dose (Gy/GyRx)
10−1

Difference from DVH TPS-calculated mean

Spinal cord: TPS

2.35 ×

Spinal cord: adjusted +60% dose error

2.40 × 10−1

1.8%

–

Au: Spinal cord: adjusted −60% dose error

2.33 × 10−1

1.1%

1.87 ×

10−1

–

Esophagus: adjusted +60% dose error

1.88 ×

10−1

0.8%

Esophagus: adjusted −60% dose error

1.86 × 10−1

0.5%

Esophagus: TPS

0.52 ×

10−1

–

0.61 ×

10−1

17.3%

Left kidney: adjusted −60% dose error

0.46 ×

10−1

11.5%

Lungs: TPS

0.57 × 10−1

Left kidney: TPS
Left kidney: adjusted +60% dose error

Lungs: adjusted +60% dose error
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Lungs: adjusted −60% dose error

–

0.59 ×

10−1

3.5%

0.56 ×

10−1

1.8%
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Volume

21.30%

10.08%

10.83%

35.73%

Organ

Colon

Bone marrow

Bone surface

Left kidney

10−2

10−2
4.07 ×

3.31 × 10−2

30.54 × 10−2
11.40 ×

2.88 × 10−2

2.54 ×

10−2

Vwt dose (Gy/GyRx)

28.58 × 10−2

11.91 ×

10−2

Mean dose (Gy/GyRx)

In-field component of dose from DVH TPS data

64.27%

89.17%

89.92%

78.70%

Volume

2.96 ×

10−2

1.08 × 10−2

1.08 × 10−2

0.78 ×

10−2

Mean dose (Gy/GyRx)

1.90 ×

10−2

0.96 × 10−2

0.97 × 10−2

0.62 ×

10−2

Vwt dose (Gy/GyRx)

Out-of-field component of dose from TLD data

5.97 × 10−2

4.27 × 10−2

3.85 × 10−2

3.16 × 10−2

Total dose (Gy/GyRx)

Volume-weighted

In-field and out-of-field components of dose and final volume-weighted (Vwt) mean organ doses for four partially in-field organs: colon, bone marrow,
bone surface and left kidney.
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